Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
In a 2018 randomized, placebo-controlled pilot study of 36 mercury-exposed gold miners in Zaruma, Ecuador, the group taking 300 mg/day of investigational NBMI (Emeramide) showed a statistically significant drop in physical fatigue scores and significantly lower urinary mercury (unadjusted) compared with placebo after 14 days. No serious adverse events were reported. NBMI is not FDA-approved.
Clinical Trials
The most current, up-to-date information on our clinical trials.